Buy PT-141 Online | The A-Z Guide

Home > Products > PT-141

buy pt-141

PT-141 is a synthetic peptide analogue of α-melanocyte-stimulating hormone (α-MSH), also referred to as bremelanotide, its generic clinical name. The peptide engages the melanocortin receptors, binding primarily to MC-4R, which is involved in the regulation of metabolism, sexual behavior, and male erectile function.

 

While bremelanotide is already an FDA-approved treatment for hypoactive sexual desire disorder in women, peptide researchers are actively investigating the compound for its effects on male sexual function and as a treatment alternative to medications like Viagra and Cialis.

  • FREE Shipping for orders over $200 (USA Only)
  • $15.00 Flat Rate Shipping Worldwide (Most Countries)
  • Includes one 30mL Bacteriostatic Water with orders over $400
PinClipart.com_usa-flag-clip-art_5738665
Table Of Contents
    Add a header to begin generating the table of contents

    What Is PT-141?

    PT-141 is a heavily modified synthetic derivative of the alpha-melanocyte-stimulating hormone. It acts as an agonist to the melanocortin-4 and melanocortin-1 receptors and is commonly referred to as bremelanotide.

    In 2019, PT141 (bremelanotide) was approved by the United States Food and Drug Administration (FDA) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. It is considered to be a safe and well-tolerated drug that can be self-administered via subcutaneous injection approximately 45 minutes before sexual activity [1].

    pt-141

    Benefits of PT-141

    PT-141 is an FDA-approved drug for the treatment of HSDD and has been extensively tested in several Phase 2 and Phase 3 clinical trials. However, findings from other studies suggest that it may offer additional benefits, potentially warranting further research. Here are the top 5 benefits of PT-141 according to the latest literature.

    Safe Treatment for Hypoactive Sexual Desire Disorder (HSDD)

    PT-141’s main benefit is that it is a safe and effective FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in female patients. In this context, PT-141 has been shown to “increase sexual desire elements” and reduce “distress related to sexual desire” when administered subcutaneously approximately 45 minutes prior to sexual activity [1].

    The latest research indicates that PT-141 increases female sexual desire by “activating presynaptic MC4Rs on neurons in the mPOA of the hypothalamus, leading to increased release of dopamine (DA)” [2] However, further research may be necessary to gain a more complete understand of PT-141’s exact mechanism of action.

    Increases Sexual Satisfaction in Premenopausal Women Suffering From Sexual Dysfunction

    Another key benefit of PT-141 is that it appears to increase sexual satisfaction in premenopausal women who suffer from sexual dysfunction. A randomized, placebo-controlled dose-finding trial found that PT-141 produced an increase in the number of “satisfying sexual events per month” when self-administered subcutaneously at doses of 0.75, 1.25, or 1.75 mg over 12 weeks (Clayton et al., 2016). The study found that 1.25 mg and 1.75 mg doses produced a +0.7 and +3.6 improvement respectively in the female sexual function index total score [3].

    Reduces Distress Caused by Low Sexual Desire in Premenopausal Women With Hypoactive Sexual Desire Disorder

    In a review of data from two randomized phase 3 trials, researchers concluded that PT-141 was able to reduce “distress related to low sexual desire” in premenopausal women suffering from hypoactive sexual desire disorder (Kingsberg et al., 2019) [4].

    Creates an Erectile Response in Healthy Males With an Inadequate Response to Sildenafil (Viagra)

    PT-141 has been shown to help healthy men who have an inadequate response to sildenafil (Viagra) achieve an erectile response. A 2004 study found that when administered at doses of 0.3 to 10 mg, PT-141 had a “statistically significant” effect on the ability of male patients to achieve an erection (Rosen et al., 2004) [5].

    Increases Intercourse Satisfaction in Men With Erectile Dysfunction

    According to a 2008 randomized, double-blind, placebo-controlled study, PT-141 helped improve intercourse satisfaction in men with erectile dysfunction who did not respond to sildenafil (Viagra). A total of 51 patients (33.5%) experienced “positive clinical results” after taking 10 mg PT-141 as an intranasal spray 45 minutes to 2 hours prior to intercourse (Safarinejad et al. 2008) [6].

    Now that we've briefly reviewed the five key benefits of PT-141, it’s time to look at this research chemical’s side effects.

    PT-141 Side Effects

    According to data from Phase 2 and Phase 3 trials of PT-141, this peptide appears to be safe and well-tolerated when administered for the treatment of HSDD. The most common adverse effects include nausea (39.9%), facial flushing (20.4%), and headaches (11%) [1].

    In terms of PT-141’s long-term safety for treating HSDD, researchers noted that of the 856 eligible patients who completed a 24-week double-blind core Phase 3 trial in 2015, 684 patients elected to participate in the 52-week open-label extension, and 272 completed it. The most common treatment-emergent adverse events (AEs) related to PT-141 administration were nausea (40.4%), flushing (20.6%), and headache (12.0%). The only severe AE that occurred during the open-label extension was nausea (Simon et al., 2019) [7].

    A review of Responder Analyses from the Phase 2b Dose-Ranging Study of PT-141 revealed that this peptide was “safe and well tolerated” by participants (Althof et al., 2019) [8].

    A review of PT-141 for the treatment of HSDD found that it has “limited drug-drug interactions, including no clinically significant interactions with ethanol” and is safe when self-administered within the prescribing guidelines of a maximum one dose per 24 hours and a maximum of 8 doses per month [9].

    PT-141 was deemed safe enough to be granted approval by the US FDA in 2019 and has not been found to cause serious adverse events or side effects at a “statistically significant” rate [10]. However, it has since been reported that PT-141 can cause mild serum enzyme elevations; rarely, it has been implicated in acute liver injury [11].

    In trials involving male patients, researchers in the 2004 trial noted that “PT-141 (bremelanotide) was safe and well tolerated in both studies” (Rosen et al., 2004) [5]. Researchers in the 2008 trial noted that while “more drug-related adverse effects occurred in the bremelanotide group” compared with the placebo group, it was generally well tolerated (Safarinejad et al. 2008) [6].

    PT-141 was cited by Kim S et al. as a novel emerging therapy for ED; however, the authors cautioned that such therapies “still need to be validated by well-designed clinical trials” [12].

    Where To Buy PT-141 Online?

    Researchers curious about where to buy bremelanotide online, will note that many vendors offer this peptide for sale. However, PT-141’s available as a research chemical is limited to qualified researchers and it cannot be purchased for self-administration or recreational purposes.

    Finding a safe, dependable, and trustworthy source of research-grade PT-141 is far from straightforward, even for qualified and well-informed researchers. This is due to the fact that the synthesis and sale of peptides is largely unregulated in many countries, and a plethora of websites claim to offer PT-141 but fail to deliver.

    So which vendor can researchers trust?

    Our staff has investigated a number of sellers and conducted test purchases to see which businesses are trustworthy and which ones fall short of their promises. Peptide Sciences, in our opinion, provides the best buying experience of any vendor, and here's why:

    • Independently Tested Peptides: Peptide Sciences is the only peptide supplier that gets each batch of peptides evaluated by a third-party lab. These third-party testing demonstrate that the peptides are pure (99 percent) and have passed rigorous tests. Researchers can view test certificates on Peptide Sciences' website before placing an order.
    • Impressive Customer Service Team: Peptide Sciences has a fantastic customer service team that is available by phone and email 24 hours a day, 7 days a week. This ensures that, in the unlikely event that a problem arises after researchers place an order, the problem will be resolved quickly and professionally.
    • Big Discounts on Bulk Orders: PT-141 10 mg vials can be purchased for just $47.5 through Peptide Sciences. Researchers can save an additional 14% by ordering in bulk, bringing the cost per vial down to just $41.
    • Comprehensive Website: Peptide Sciences’ website is absolutely packed with useful information regarding peptides like bremelanotide. Researchers new to PT-141 will find a lot of information on the use, advantages, and adverse effects of this peptide.
    • Great Value Shipping: Peptide Sciences charges a fixed rate of $15 for all international deliveries and waives the shipping fee on orders exceeding $100 in the United States. A complimentary 30 mL vial of bacteriostatic water is included with orders over $300.

    After reviewing all of the top peptide sellers on the market, our staff is in no doubt that Peptide Sciences offers the best purchasing experience and provides the best value for money. Researchers can get pure bremelanotide in bulk and save a significant amount when they order here. Peptide Sciences is incredibly dependable and trustworthy and would be a terrific vendor for your next study.

    Buy PT-141 from the #1 online Peptides vendor in the world...

    Verdict

    In this guide about where to buy PT-141 online, we aimed to answer any queries researchers may have had about where to buy this peptide and how to find it at the best prices. As previously stated, PT-141 is an FDA-approved drug used to treat hypoactive sexual desire disorder (HSDD) and it is also available online as a research chemical to qualified researchers.

    PT-141 offers a lot of potential for additional research, notably to treat sexual dysfunction. More specifically, it has been qualified as a potential alternative treatment of erectile dysfunction in healthy males who do not otherwise respond to Viagra. Researchers may consider Peptide Sciences if they are looking for a dependable supplier for their next research project.

    pt-141

    References

    1. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020 Jul;54(7):684-690. doi: 10.1177/1060028019899152. Epub 2020 Jan 1. PMID: 31893927.
    2. Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2021 Jan 18:1-9. doi: 10.1017/S109285292100002X. Epub ahead of print. PMID: 33455598.
    3. Clayton, A. H., Althof, S. E., Kingsberg, S., DeRogatis, L. R., Kroll, R., Goldstein, I., Kaminetsky, J., Spana, C., Lucas, J., Jordan, R., & Portman, D. J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's health (London, England), 12(3), 325–337. https://doi.org/10.2217/whe-2016-0018
    4. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PMID: 31599840; PMCID: PMC6819021.
    5. Rosen, R. C., Diamond, L. E., Earle, D. C., Shadiack, A. M., & Molinoff, P. B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International journal of impotence research, 16(2), 135–142. https://doi.org/10.1038/sj.ijir.3901200
    6. Safarinejad, M. R., & Hosseini, S. Y. (2008). Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of urology, 179(3), 1066–1071. https://doi.org/10.1016/j.juro.2007.10.063
    7. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019 Nov;134(5):909-917. doi: 10.1097/AOG.0000000000003514. PMID: 31599847; PMCID: PMC6819023.
    8. Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J, Spana C. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019 Aug;16(8):1226-1235. doi: 10.1016/j.jsxm.2019.05.012. Epub 2019 Jul 2. PMID: 31277966.
    9. Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. Med Lett Drugs Ther. 2019 Jul 29;61(1577):114-116. PMID: 31381550.
    10. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019 Sep;79(14):1599-1606. doi: 10.1007/s40265-019-01187-w. PMID: 31429064.
    11. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Bremelanotide. 2021 Aug 20. PMID: 34436837.
    12. Kim S, Cho MC, Cho SY, Chung H, Rajasekaran MR. Novel Emerging Therapies for Erectile Dysfunction. World J Mens Health. 2021 Jan;39(1):48-64. doi: 10.5534/wjmh.200007. Epub 2020 Mar 16. PMID: 32202086; PMCID: PMC7752520.